SANUWAVE Health, Inc. Provides Earning Guidance for Second Quarter of 2024
July 10, 2024 at 07:06 am
Share
SANUWAVE Health, Inc. provided earning guidance for second quarter of 2024. For the quarter the company expects revenues to be in the range of $7.0 to $7.2 million, an increase of 50% to 54% over Second Quarter 2023 and consistent with the upper end of the range of guidance given in the Company?s First Quarter 2024 earnings release from May 10, 2024.
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. The Company is a provider of Food and Drug Administration (FDA)-approved wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and others. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression (PACE) technology to converge at precise selected targets to produce an extremely short duration compression burst.
SANUWAVE HEALTH, INC. 
